FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3028614809> ?p ?o ?g. }

• W3028614809 endingPage "9502" @default.
• W3028614809 startingPage "9502" @default.
• W3028614809 abstract "9502 Background: First-line therapy for advanced NSCLC includes PD-1 checkpoint inhibitor (ICI) monotherapy, and in combination with chemotherapy. Combination ICI have also demonstrated better survival compared to chemotherapy (CM-227). In CCTG BR.34, we compared overall survival (OS) in patients with advanced NSCLC receiving first-line durvalumab plus tremelimumab (DT) with or without platinum doublet chemotherapy (CT). Methods: This international, open-label, randomized trial accrued 301 participants from Canada and Australia, with stage IV NSCLC, EGFR/ALK wildtype, ECOG PS 0/1. Patients were randomized to DT for 4 cycles or DT+CT (pemetrexed- or gemcitabine-platinum), with ongoing D or D + pemetrexed (non-squamous) maintenance until disease progression. Stratification factors included histology, stage IVA v. IVB and smoking status. The primary endpoint was OS; secondary endpoints included progression-free survival (PFS), objective response rate (ORR = CR + PR) and adverse events (AEs). Results: At a median follow up of 16.6 months, no significant difference in OS was seen between the two treatment arms, with a median OS of 16.6 months with DT+CT v. 14.1 months with DT, (estimated HR 0.88, 90% CI 0.67-1.16). PFS was significantly improved in the DT+CT arm (stratified HR 0.67, 95% CI 0.52-0.88; medians 7.7 v. 3.2 months). ORR was higher in the DT+CT arm, 28% v. 14%, (odds ratio 2.1, p=0.001). Preplanned subgroup analysis demonstrated no significant differences in treatment outcomes by plasma TMB (<20 v. ≥20 mut/Mb, Guardant OMNI), age, sex, or smoking status. There was a trend to improved OS with DT+CT in the subgroup with PD-L1 TPS≥50%, (HR 0.64, 95% CI 0.40-1.04, p=0.07). Plasma TMB<20 mut/Mb was associated with shorter survival in both treatment groups (HR 1.99, 95% 1.3-3.1). Toxicity was greater in the DT+CT arm, with grade≥3 adverse events in 82% v. 70%, (p=0.02), most commonly dyspnea, nausea and cough. The incidence of immune-related adverse events was similar between arms (colitis 11%, pneumonitis 6%, endocrinopathy 21%). Grade 5 events occurred in 2.7%, (5 with DT+CT, 3 with DT). Conclusions: The addition of CT to first-line DT did not improve OS in advanced NSCLC. CT+DT improved ORR and PFS, and was associated with greater toxicity. No differential effects were seen by PD-L1 TPS nor bTMB. These data suggest that adding chemotherapy to ICI may be beneficial in those with PD-L1 TPS >=50%, and warrant further analysis in independent datasets. Clinical trial information: NCT03057106 ." @default.
• W3028614809 created "2020-06-05" @default.
• W3028614809 creator A5002916492 @default.
• W3028614809 creator A5009677422 @default.
• W3028614809 creator A5011285948 @default.
• W3028614809 creator A5011528245 @default.
• W3028614809 creator A5012748795 @default.
• W3028614809 creator A5015598221 @default.
• W3028614809 creator A5018835840 @default.
• W3028614809 creator A5022724085 @default.
• W3028614809 creator A5028362380 @default.
• W3028614809 creator A5030689616 @default.
• W3028614809 creator A5044298903 @default.
• W3028614809 creator A5045996745 @default.
• W3028614809 creator A5048952656 @default.
• W3028614809 creator A5056133781 @default.
• W3028614809 creator A5061662378 @default.
• W3028614809 creator A5061757629 @default.
• W3028614809 creator A5077884585 @default.
• W3028614809 creator A5084167063 @default.
• W3028614809 creator A5089797416 @default.
• W3028614809 date "2020-05-20" @default.
• W3028614809 modified "2023-10-10" @default.
• W3028614809 title "CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC)." @default.
• W3028614809 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.9502" @default.
• W3028614809 hasPublicationYear "2020" @default.
• W3028614809 type Work @default.
• W3028614809 sameAs 3028614809 @default.
• W3028614809 citedByCount "22" @default.
• W3028614809 countsByYear W30286148092020 @default.
• W3028614809 countsByYear W30286148092021 @default.
• W3028614809 countsByYear W30286148092022 @default.
• W3028614809 countsByYear W30286148092023 @default.
• W3028614809 crossrefType "journal-article" @default.
• W3028614809 hasAuthorship W3028614809A5002916492 @default.
• W3028614809 hasAuthorship W3028614809A5009677422 @default.
• W3028614809 hasAuthorship W3028614809A5011285948 @default.
• W3028614809 hasAuthorship W3028614809A5011528245 @default.
• W3028614809 hasAuthorship W3028614809A5012748795 @default.
• W3028614809 hasAuthorship W3028614809A5015598221 @default.
• W3028614809 hasAuthorship W3028614809A5018835840 @default.
• W3028614809 hasAuthorship W3028614809A5022724085 @default.
• W3028614809 hasAuthorship W3028614809A5028362380 @default.
• W3028614809 hasAuthorship W3028614809A5030689616 @default.
• W3028614809 hasAuthorship W3028614809A5044298903 @default.
• W3028614809 hasAuthorship W3028614809A5045996745 @default.
• W3028614809 hasAuthorship W3028614809A5048952656 @default.
• W3028614809 hasAuthorship W3028614809A5056133781 @default.
• W3028614809 hasAuthorship W3028614809A5061662378 @default.
• W3028614809 hasAuthorship W3028614809A5061757629 @default.
• W3028614809 hasAuthorship W3028614809A5077884585 @default.
• W3028614809 hasAuthorship W3028614809A5084167063 @default.
• W3028614809 hasAuthorship W3028614809A5089797416 @default.
• W3028614809 hasConcept C121608353 @default.
• W3028614809 hasConcept C126322002 @default.
• W3028614809 hasConcept C143998085 @default.
• W3028614809 hasConcept C168563851 @default.
• W3028614809 hasConcept C203092338 @default.
• W3028614809 hasConcept C2776256026 @default.
• W3028614809 hasConcept C2776694085 @default.
• W3028614809 hasConcept C2777240266 @default.
• W3028614809 hasConcept C2777701055 @default.
• W3028614809 hasConcept C2777742743 @default.
• W3028614809 hasConcept C2778239845 @default.
• W3028614809 hasConcept C2778650287 @default.
• W3028614809 hasConcept C2780057760 @default.
• W3028614809 hasConcept C2780258809 @default.
• W3028614809 hasConcept C2781433595 @default.
• W3028614809 hasConcept C71924100 @default.
• W3028614809 hasConceptScore W3028614809C121608353 @default.
• W3028614809 hasConceptScore W3028614809C126322002 @default.
• W3028614809 hasConceptScore W3028614809C143998085 @default.
• W3028614809 hasConceptScore W3028614809C168563851 @default.
• W3028614809 hasConceptScore W3028614809C203092338 @default.
• W3028614809 hasConceptScore W3028614809C2776256026 @default.
• W3028614809 hasConceptScore W3028614809C2776694085 @default.
• W3028614809 hasConceptScore W3028614809C2777240266 @default.
• W3028614809 hasConceptScore W3028614809C2777701055 @default.
• W3028614809 hasConceptScore W3028614809C2777742743 @default.
• W3028614809 hasConceptScore W3028614809C2778239845 @default.
• W3028614809 hasConceptScore W3028614809C2778650287 @default.
• W3028614809 hasConceptScore W3028614809C2780057760 @default.
• W3028614809 hasConceptScore W3028614809C2780258809 @default.
• W3028614809 hasConceptScore W3028614809C2781433595 @default.
• W3028614809 hasConceptScore W3028614809C71924100 @default.
• W3028614809 hasFunder F4320334576 @default.
• W3028614809 hasIssue "15_suppl" @default.
• W3028614809 hasLocation W30286148091 @default.
• W3028614809 hasOpenAccess W3028614809 @default.
• W3028614809 hasPrimaryLocation W30286148091 @default.
• W3028614809 hasRelatedWork W2020996031 @default.
• W3028614809 hasRelatedWork W2044560382 @default.
• W3028614809 hasRelatedWork W2754251024 @default.
• W3028614809 hasRelatedWork W2898134598 @default.
• W3028614809 hasRelatedWork W2947833191 @default.
• W3028614809 hasRelatedWork W3153820261 @default.
• W3028614809 hasRelatedWork W3200440666 @default.
• W3028614809 hasRelatedWork W4225883630 @default.

• next